Credelio (lotilaner) is an FDA-approved medication used for flea and tick control in dogs [1]. Information regarding its patent expiration can be found within the FDA's Green Book, which lists approved drug products with national patent and exclusivity information [2].
When does lotilaner's patent protection end?
Patent expiration dates for lotilaner are available through resources that track pharmaceutical intellectual property, such as DrugPatentWatch.com [3]. These patents typically cover the composition of matter, formulation, and methods of use for the drug [3]. Once patents expire, generic or biosimilar versions of the drug may become available, potentially lowering costs [3].
What is lotilaner's regulatory status?
Lotilaner received FDA approval for its use in veterinary medicine [1]. The FDA Green Book provides details on approved drugs, including their patent and exclusivity status, which is crucial for understanding market exclusivity and potential generic entry [2].
How does lotilaner work to kill fleas and ticks?
Lotilaner is an ectoparasiticide that belongs to the isoxazoline class [1]. It works by inhibiting GABA-gated and glutamate-gated chloride channels in the nervous system of fleas and ticks. This disruption leads to rapid excitation and death of the parasites [1].
Who manufactures Credelio (lotilaner)?
Credelio is manufactured by Elanco Animal Health [4]. Elanco is a global animal health company that develops and markets a wide range of products for pets and livestock [4].
What is the difference between lotilaner and other flea and tick treatments?
Lotilaner is distinguished by its rapid onset of action, providing quick relief from flea and tick infestations [1]. Compared to older treatments, isoxazolines like lotilaner offer a different mechanism of action, which can be important in managing parasite resistance [5]. Other common treatments include fipronil, imidacloprid, and selamectin, each with varying active ingredients and durations of effectiveness [5].
Where can I find official FDA information on lotilaner?
The official FDA Green Book is the primary source for information on approved drug products and their patent and exclusivity information [2]. This resource is essential for veterinarians, pharmacists, and manufacturers seeking to understand the regulatory and intellectual property landscape of medications like lotilaner [2].
What are the potential risks or side effects of lotilaner?
While generally considered safe and effective, like all medications, lotilaner can have potential side effects [1]. These are typically mild and transient, and may include neurological effects such as tremors or lethargy in rare cases [1]. Owners should always consult their veterinarian regarding any concerns about their pet's health and medication [1].
How does patent expiration impact the availability of generic lotilaner?
Upon the expiration of relevant patents and exclusivity periods, generic versions of lotilaner can be developed and submitted for FDA approval [3]. The availability of generics usually leads to increased competition and often a reduction in the price of the medication [3]. DrugPatentWatch.com tracks these patent timelines to anticipate generic market entry [3].
Sources:
[1] https://www.fda.gov/animal-veterinary/product-safety/drug-approvals-and-continuing-investigations-animal-drugs
[2] https://www.fda.gov/drugs/information-on-drugs/frequently-asked-questions-fdas-approved-drug-products-electronic-database-fdalist
[3] https://drugpatentwatch.com/
[4] https://www.elanco.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070958/